Sign up online today & collaborate
or click here to find out more
Optibrium, a developer of software for small molecule discovery, today announced that Janssen Research and Development has signed an agreement to license Optibrium’s StarDrop software. The agreement will provide a global licence for StarDrop and eight of StarDrop’s optional plug-in modules.
StarDrop is a software suite that helps researchers to deliver optimally balanced, successful compounds. It brings confidence and intuitive simplicity to decision making; guiding and validating the direction taken by project teams and which compounds are prioritized. StarDrop works by evaluating project teams’ complex data, which is often uncertain because of experimental variability or predictive error. Its interactive tools then enable researchers to efficiently explore ways to further improve their chosen compounds. StarDrop's core features can also be extended with a range of optional plug-in modules that provide comprehensive capabilities for compound optimisation, including: Predictive models for ADME properties, P450 metabolism and toxicity; automatic QSAR model building; 3D structure-activity relationships; and de novo design to stimulate the search for new optimisation strategies.
Dr Matthew Segall, Optibrium’s CEO, commented, “Optibrium and Janssen have enjoyed a long history of collaboration and we are delighted that this has expanded into a worldwide partnership with StarDrop being selected to help guide their global drug discovery research efforts.”
For further information on Optibrium and StarDrop, please visit www.optibrium.com/stardrop/, contact firstname.lastname@example.org or call +44 1223 815900.
Zyme Communications E-mail: email@example.com Phone: +44 (0) 7771 730919
Director, Business Development E-mail: firstname.lastname@example.org
Phone: +44 (0)1223 815900
About Optibrium Ltd.
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s portfolio of products includes:
• StarDrop™, which brings confidence to the selection and design of high quality candidate compounds. StarDrop creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective candidate compounds with a high probability of success downstream.
• Sentira™, an easy-to-use, dynamic data visualisation platform that helps to quickly spot patterns in compound data, analyse structure-activity relationships and elegantly present and report results.
• Asteris™, an iPad app that enables researchers to explore new compound ideas when and where they want, by combining highly intuitive chemistry drawing tools with StarDrop’s visually informative predictive modelling.
Founded in 2009, Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.
Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.
7221 Cambridge Research Park
Beach Drive, Cambridge
CB25 9TL, UK
Tel: +44 1223 815900
Fax: +44 1223 815907
Optibrium Limited, registered in England and Wales No. 06715106. Optibrium™, StarDrop™, Glowing Molecule™ and Nova™ are trademarks of Optibrium Ltd. Derek Nexus™ is a trademark of Lhasa Ltd., BIOSTER™ is a trademark of Digital Chemistry Ltd., torch3D™ is a trademark of Cresset Biomolecular Research Ltd and Matsy™ is a trademark of NextMove Software Ltd..